Difference Between Avatrombopag and Hatrombopag

Avatrombopag and heltrombopag are two different drugs. Although they are both used to treat related diseases such as thrombocytopenia, they are significantly different in many aspects.

From a mechanism of action perspective, although avatrombopag and heltrombopag are both thrombopoietin receptor agonists (TPO-RAs), their modes of action are different. Avatrombopag is a small molecule peptide TPO-RA drug that stimulates the proliferation, differentiation and release of platelet precursor cells in the bone marrow by binding to the TPO receptor, thereby increasing the number of platelets in the body. Hetrombopag is a non-peptide TPO-RA drug that increases the number of platelets in the body by activating platelet production, binds to the thrombopoietin receptor (TPO receptor), stimulates stem cells in the bone marrow to differentiate into platelets, and promotes the growth and maturation of platelets.

There are also differences in the medication methods between avatrombopag and heltrombopag. Avatrombopag is usually given as an oral medication once daily, with the dose adjusted based on the patient's weight and platelet count. Hatrombopag is also given to patients in the form of oral medication, usually once a day, and the dose will also be determined according to the patient's specific condition. However, the specific dosage and frequency of medication need to be determined based on the doctor's recommendations and the patient's specific situation.

Avatrombopag and heltrombopag also differ in their side effects. Common side effects of avatrombopag may include headache, fatigue, gastrointestinal discomfort, etc., while common side effects of heltrombopag may include headache, fatigue, nausea, etc. Therefore, when using these two drugs, patients need to pay special attention to the possible occurrence of these adverse reactions and promptly report any uncomfortable symptoms to their doctor.